Medical Rationale
Glaucoma produces progressive, irreversible peripheral visual field loss that triggers significant psychological distress. Unlike sudden vision loss, the insidious progression of glaucomatous field loss creates chronic anticipatory anxiety about eventual blindness — a phenomenon distinct from other vision-threatening conditions. Peripheral field loss impairs spatial navigation, driving ability, and fall avoidance, producing functional dependence and social isolation. The treatment burden compounds psychological distress: topical medication side effects (ocular irritation, fatigue), laser procedures, and filtration surgeries create a chronic illness identity. Depression prevalence in glaucoma patients is 10-25%, with anxiety rates of 13-30%, significantly exceeding age-matched controls. Glaucoma medication adherence — critical for preventing progression — paradoxically worsens when depression develops, creating a cycle of disease progression and psychological decline.
Key Studies
Zhang X et al. (2013) Ophthalmology (depression and anxiety in glaucoma — systematic review and meta-analysis); Mabuchi F et al. (2012) Am J Ophthalmol (depression and quality of life in patients with glaucoma).
Filing Tips
Psychiatric evaluation documenting depression or anxiety diagnosis. Humphrey visual field testing documenting progressive field loss. Ophthalmology records showing glaucoma severity and treatment history. Functional assessment documenting impact on driving, mobility, and ADLs. Psychiatry nexus letter addressing the vision loss → functional impairment → depression mechanism. Document any medication non-adherence due to depression, as this supports the bidirectional relationship. File under DC 9434 (depression) or DC 9400 (anxiety) depending on the predominant presentation.